

Anti-obesity effects of medicinal plants from Asian countries and related molecular mechanisms: a review

Sangwon Chung¹, Soo Hyun Park¹, Jae Ho Park¹, Jin-Taek Hwang^{1,2,*}

¹Research Group of Healthcare, Korea Food Research Institute, 55365 Jeollabuk-do, Republic of Korea

²Department of Food Biotechnology, University of Science and Technology, 34113 Daejeon, Republic of Korea

*Correspondence: jthwang@kfri.re.kr (Jin-Taek Hwang)

DOI: [10.31083/j.rcm2204135](https://doi.org/10.31083/j.rcm2204135)

This is an open access article under the CC BY 4.0 license (<https://creativecommons.org/licenses/by/4.0/>).

Submitted: 20 August 2021 Revised: 20 September 2021 Accepted: 14 October 2021 Published: 22 December 2021

Medicinal plants have been used as an alternative medicine for obesity prevention, and Asian countries, which are major habitats of various medicinal plant species, have traditionally used these medicines for centuries. Obesity is a global health problem caused by excessive fat accumulation linked to abnormal lipid metabolism, such as adipogenesis, lipogenesis, and lipolysis. Accordingly, the effects of medicinal plants on obesity-related mechanisms and biomarkers have been evaluated in various experimental studies. For example, adipogenesis and lipogenesis are regulated by several transcription factors, such as peroxisome proliferator-activated receptor gamma, CCAAT/enhancer binding protein alpha, and fatty acid synthase. Moreover, activation of the adenosine monophosphate-activated protein kinase pathway is accompanied by promotion of lipolysis. However, few reports have consolidated studies of the effects of various Asian medicinal plants on obesity and related mechanisms. Therefore, in this review, we examined the associations of medicinal plants originating from Asian countries with obesity and discussed the related mechanisms and biomarkers from *in vitro* and *in vivo* studies.

Keywords

Medicinal plants; Asia; Obesity; Adipogenesis; Biomarker; Review

1. Introduction

Obesity is a global health problem that is expected to continuously increase in incidence in upcoming years [1]. According to the World Health Organization (WHO), in 2016, more than 650 million adults (approximately 13% of the population) worldwide were considered obese [2]. Because obesity causes various health complications, including insulin resistance, hepatic steatosis, and dyslipidemia [3–5], obesity is considered a major risk factor for chronic diseases, such as type 2 diabetes, cardiovascular diseases, and cancer [6, 7]. Thus, obesity prevention and management are essential for individual health and the national healthcare system.

To prevent obesity, it is generally recommended to reduce energy intake and improve lifestyle. When obesity becomes severe, anti-obesity drugs have been used as a mechanism to promote metabolism and suppress appetite; however, the use of these drugs is often limited owing to various side effects, such as neuropathy and cardiovascular disease [8]. For example, the appetite suppressant sibutramine was widely used

after approval, but was then withdrawn from the market in 2010 due to the risk of cardiovascular disease [8]. Obesity is currently treated with long-term use of anti-obesity drugs that target various mechanisms of action, including gastric/pancreatic lipases, neurotransmitters, glucagon-like peptide-1 (GLP-1) analogs, and catecholamine release [9]. However, these drugs have been reported to exhibit various side effects, including insomnia, vomiting, hyperpyrexia, and constipation [9].

Accordingly, medicinal plants have emerged as alternative preventive agents because of their weak side effects, ease of availability, low cost, and richness in bioactive compounds [10]. A recent meta-analysis of clinical trials demonstrated that intake of green tea, *Phaseolus vulgaris*, and *Nigella sativa* improved obesity-related parameters, such as weight, body mass index, waist circumference, and lipid levels [11]. In addition, several plants, including garcinia and Yerba mate, have been developed as dietary supplements for weight management [12–14], and weight loss products in the form of pills have widely used for obesity management [15, 16].

Medicinal plants are currently used worldwide; in particular, Asian countries, including China, Japan, Thailand, Indonesia, and Himalayan countries, have traditionally used medicinal plants for more than two centuries [17–20]. Asian medicinal plants also account for 45% of global profits in trades of medicinal plants, and approximately 39,000 species of medicinal plants are found naturally in Asian countries [21, 22]. However, an overview of the effects of various Asian medicinal plants on obesity and related mechanisms has rarely been reported.

Therefore, in this study, we study aimed to examine the association of medicinal plants originating from Asian countries with obesity and related mechanisms and biomarkers *in vitro* and *in vivo*.

2. Obesity related mechanisms and biomarkers

The development of obesity can be influenced by various factors, such as diet, physical activity, environment and genetic susceptibilities [23]. In general, however, obesity is

simply defined as status of abnormal fat accumulation in adipose tissue, and caused by excessive fat accumulation resulting from an imbalance between high energy intake and low energy expenditure at the cellular level [23]. Adipose tissue consists of white adipose tissue and brown adipocytes. White adipose tissue stores energy in the form of lipids or breaks down stored lipids to use them when energy is needed, whereas brown adipocytes use them to generate heat and contain large numbers of mitochondria [24]. In particular, adipose tissue generates heat and consumes energy through regulation of various proteins, such as uncoupling protein 1 (UCP1) [25]. Fat accumulation includes adipogenesis, which involves accumulation of lipids in the form of triglycerides (TGs) in adipocytes and increased size of adipocytes [26, 27]. Lipolysis, which is the alteration of stored TG to free fatty acids and glycerol, is also a process of abnormal lipid metabolism [28]. In addition, obesity is followed by dyslipidemia, which is characterized by high TG levels and low high-density lipoprotein cholesterol or high low-density lipoprotein cholesterol (LDL-C) levels [29].

Various adipogenic markers are also involved in the development of obesity. Expression of CCAAT/enhancer binding protein (C/EBP) β and C/EBP δ during adipogenesis induces the expression of C/EBP α and peroxisome proliferator-activated receptor gamma (PPAR γ), resulting in the expression of fatty acid synthase (FAS) and fatty acid binding protein 4 (FABP4) [24, 30]. Fatty acids act as ligands of PPAR γ , and adipocyte protein 2 (aP2) affects the transport and metabolism of intracellular fatty acids into cells [24, 30]. In addition, the expression of sterol regulatory element binding protein-1c (SREBP1c) cooperates with C/EBP α and PPAR γ to increase the expression of aP2 and FAS [24, 30]. The expression of SREBP1c is also related to the expression of acetyl-CoA carboxylase (ACC) [31]. ACC, a controller of malonyl-CoA, allosterically inhibits the expression of carnitine palmitoyl transferase-1 (CPT-1), thereby inhibiting β -oxidation [32]. During adipose tissue development, the expression of adipokines, which are secreted by adipose tissue, is regulated by several transcription factors, including PPAR γ and C/EBP α [33, 34]. Therefore, inhibition of various adipogenic markers is widely used to develop effective drugs or natural agents for obesity.

3. General characteristics of Asian medicinal plants

We searched articles from PubMed and Google Scholar using the keywords “plant”, “obesity”, “anti-obesity”, “fat”, “lipid”, “cell”, and “mice” from April 2019 to October 2020. We considered only *in vitro* and *in vivo* studies using medicinal plants that generally originated from Asian countries in the article and mainly targeted adipogenesis, lipid or fat accumulation, and obesity. Articles written in languages other than English were excluded. As a result, fourteen medicinal plants from 12 articles were reviewed. We extracted the following information from the articles: general characteristics

of medicinal plants, including order, family, genus, scientific name, major habitat, extraction method, plant part, and major components; *in vitro* or *in vivo* models used in the article; administration and dose; anti-obesity activities, such as anti-adipogenesis; and related biomarkers. The characteristics of medicinal plants were based on information in the original article; however, several parameters, including order, family, and genus, which were not specified in the original article, were based on the information of the National Institute of Biological Resources of the Ministry of Environment in Korea (URL: <https://species.nibr.go.kr/>).

The general characteristics of the Asian medicinal plants are described in Table 1 (Ref. [35–46]). The major habitat countries are North East Asia, including Korea, China, and Japan, as well as India, Malaysia, and Russia. In total, 11 orders, 12 families, and 14 genera were identified. The orders and families of medicinal plants were Apiales-Araliaceae, Asterales-Asteraceae, Capparales-Brassicaceae, Moringaceae, Cornales-Cornaceae, Dipsacales-Valerianaceae, Myrtales-Melastomataceae, Nymphaeales-Nelumbonaceae, Rosales-Saxifragaceae, Sapindales-Aceraceae, Urticales-Moraceae, and Violales-Violaceae. The types of plant extraction were generally water and ethanol, although petroleum ether and methanol were also used. The major compounds in medicinal plants were flavonoids, such as quercetin, as well as catechin, rutin, and phenolic acids. The effects of medicinal plants were demonstrated using *in vitro* models in nine studies and *in vivo* models in eight studies (Table 1).

4. Anti-obesity effects of Asian medicinal plants and their underlying mechanisms *in vitro*

All *in vitro* studies selected in this study used 3T3-L1 cells to examine the effects of Asian medicinal plants on adipogenesis, lipogenesis, lipolysis, and other obesity-related activities (Table 2, Ref. [35, 36, 38–41, 44]). Adipogenesis, also called adipocyte differentiation, is a process through which preadipocytes develop into mature adipocytes [47]. Adipocytes are major components of white adipose tissue that mediate physiological and pathological processes, such as appetite, immunological and inflammatory responses, glucose metabolism, and blood pressure regulation [47, 48]. 3T3-L1 cells are pre-adipocytes that originate from mouse embryonic fibroblasts and have been commonly used to evaluate anti-obesity effects [49]. Notably, many medicinal plants, including *Acer okamotoanum* Nakai and *Astilbe chinensis* Franch. et Savat., *Cirsium setidens* Naki, *Cornus kousa*, *Dendropanax morbifera*, *Moringa oleifera*, and a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, attenuate pre-adipocyte differentiation by suppressing lipid accumulation and reducing the size and number of lipid droplets in adipocytes. In particular, studies of *Astilbe chinensis* Franch. et Savat., *Dendropanax morbifera*, and *Moringa oleifera* showed that these plants decrease TG accumulation in adipocytes. In

Table 1. General characteristics of Asian medicinal plants with anti-obesity effects described in this study.

Order/Family/Genus	Plant name/Scientific name	Major habitat	Reference
Apiales			
Araliaceae	<i>Dendropanax morbifera</i>	Korea (Jeju Island)	Song <i>et al.</i> [35]
Dendropanax			
Asterales			
Asteraceae	<i>Cirsium setidens</i> Naki	Korea (Gangwon province)	Cho <i>et al.</i> [36]
Cirsium			
Cosmos	<i>Cosmos caudatus</i> Kunth	Malaysia	Rahman <i>et al.</i> [37]
Solidago	<i>Solidago virgaurea</i> var. <i>gigantea</i>	North East Asia	Wang <i>et al.</i> [38]
Capparales			
Brassicaceae	<i>Raphanus Sativus</i>	China, Mostly Asia	Sim <i>et al.</i> [39]
Raphanus			
Moringaceae	<i>Moringa oleifera</i> Lam.	India, Africa	Xie <i>et al.</i> [40]
Moringa			
Cornales			
Cornaceae	<i>Cornus kousa</i>	China, Japan, Korea	Khan <i>et al.</i> [41]
Cornus			
Dipsacales			
Valerianaceae	<i>Valeriana dageletiana</i> Nakai ex F. Maek.	Korea (Ulung Island)	Wang <i>et al.</i> [42]
Valeriana			
Myrtales			
Melastomataceae	<i>Melastoma malabathricum</i> var <i>Alba</i> Linn	Malaysia	Karupiah <i>et al.</i> [43]
Melastoma			
Nymphaeales			
Nelumbonaceae	<i>Nelumbo Nucifera</i> L.	China (Mostly Asia)	Sim <i>et al.</i> [39]
Nelumbo			
Rosales			
Saxifragaceae	<i>Astilbe chinensis</i> Franch. et Savat.	Russia, China, Japan, Korea	Zhang <i>et al.</i> [44]
Astilbe			
Sapindales			
Aceraceae	<i>Acer okamotoanum</i> Nakai	Korea (Ulung Island)	Kim <i>et al.</i> [45]
Acer			
Urticales			
Moraceae	<i>Morus Alba</i> L.	China, Mostly Asia	Sim <i>et al.</i> [39]
Morus			
Violales			
Violaceae	<i>Viola mandshurica</i> W. Becker	China, Japan, Korea	Sung <i>et al.</i> [46]
Viola			

addition, extracts of *Acer okamotoanum* Nakai, *Cirsium setidens* Naki, *Cornus kousa*, *Dendropanax morbifera*, and *Moringa oleifera* inhibit lipogenesis or stimulate lipolysis. Extracts of *Cirsium setidens* Naki increase glycerol release from mature adipocytes and stimulate triglycerol lipolysis. In particular, effect of glycerol release of extracts of *Cirsium setidens* Naki was stronger than the effect of *Garcinia cambogia*, a well-known plant for anti-adipogenic and anti-lipogenesis activities [50, 51]. Extracts of *Dendropanax morbifera* inhibit lipid accumulation by reducing glucose uptake, but do not significantly decrease lipolysis.

As shown in Table 3 (Ref. [36, 40, 41, 44, 45]), the expression of adipogenesis- and lipogenesis-related biomarkers is downregulated by treatment with *Acer okamotoanum* Nakai, *Astilbe chinensis* Franch. et Savat., *Cirsium setidens* Naki, *Cornus*

kousa, *Dendropanax morbifera*, and *Moringa oleifera* in differentiated adipocytes. Additionally, treatment with *Cirsium setidens* Naki extract reduces the expression of PPAR γ , C/EBP α , C/EBP β , and C/EBP δ . Moreover, the protein expression of PPAR γ , C/EBP α , C/EBP β , SREBP1, and FAS is inhibited by *Dendropanax morbifera* and *Moringa oleifera* extracts, whereas treatment with *Acer okamotoanum* Nakai, *Astilbe chinensis* Franch. et Savat., and *Cornus kousa* extracts decreases the protein expression of PPAR γ , C/EBP α , SREBP1, and FAS. The gene expression of transcription factors, including PPAR γ , C/EBP α , C/EBP β , C/EBP δ , and SREBP1, has been reported to regulate adipogenesis and lipogenesis [47, 52]. Furthermore, FAS is a well-known enzyme related to fatty acid synthesis [53] and may inhibit fat synthesis in adipocytes following treatment with medicinal

Table 2. Anti-obesity activities of Asian medicinal plants as demonstrated using *in vitro* models.

Activities	Plants	Plant part	Extraction	Major components	Objects	Dose	References
Reduced intercellular lipid accumulation and lipid droplet sizes and numbers during adipogenesis	<i>Acer okamotoanum</i> Nakai	Leaf	Methanol extraction	-	3T3-L1 cells	P, A + None, A + 50 µg/mL, A + 100 µg/mL	Kim <i>et al.</i> [45]
	<i>Astilbe chinensis</i> Franch. et Savat.	Whole plant	Ethanol extraction	Astilbic acid (Triterpenoids)	3T3-L1 cells	P, A + None, A + 20 µg/mL, A + 40 µg/mL	Zhang <i>et al.</i> [44]
	<i>Cirsium setidens</i> Naki	Leaf	Ethanol extraction	Pectolinarin	3T3-L1 cells	P, A + PC (<i>Garcinia cambogia</i> extract) 100 µg/mL, A + 100 µg/mL, A + 200 µg/mL	Cho <i>et al.</i> [36]
	<i>Cornus kousa</i>	Leaf	Ethanol extraction	Anthocyanins	3T3-L1 cells	A + None, A + 5 µg/mL, A + 30 µg/mL, A + 60 µg/mL, A + 100 µg/mL	Khan <i>et al.</i> [41]
	<i>Dendropanax morbifera</i>	Leaf	Water extraction	Vitamin C Tannic acid	3T3-L1 cells	P, A + None, A + 50 µg/mL, A + 100 µg/mL, A + 300 µg/mL, A + 500 µg/mL	Song <i>et al.</i> [35]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	3T3-L1 cells	A + None, A + 25 µg/mL, A + 50 µg/mL, A + 100 µg/mL, A + 200 µg/mL, A + 400 µg/mL	Xie <i>et al.</i> [40]
	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Leaf, leaf, root	Ethanol extraction	Quercetin-3-O-glucuronide	3T3-L1 cells	P, A + PC (<i>Garcinia cambogia</i>) 100 µg/mL, A + EM11 ^a 100 µg/mL, A + EM12 ^b 100 µg/mL, A + EM01 ^c 100 µg/mL, A + Q3OG ^d 7.8 µM	Sim <i>et al.</i> [39]
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Whole plant	Ethanol extraction	Protocatechuic acid, Chlorogenic acid, Rutin	3T3-L1 cells	P, A + None, A + water extract 10 µg/mL, A + 10% ethanol extract 10 µg/mL, A + 30% ethanol extract 10 µg/mL, A + 50% ethanol extract 10 µg/mL, A + 70% ethanol extract 10 µg/mL, A + 100% ethanol extract 10 µg/mL	Wang <i>et al.</i> [38]
Decreased TG accumulation in adipocytes	<i>Astilbe chinensis</i> Franch. et Savat.	Whole plant	Ethanol extraction	Astilbic acid (Triterpenoids)	3T3-L1 cells	P, A + None, A + 20 µg/mL, A + 40 µg/mL	Zhang <i>et al.</i> [44]
	<i>Dendropanax morbifera</i>	Leaf	Water extraction	Vitamin C Tannic acid	3T3-L1 cells	P, A + None, A + 50 µg/mL, A + 100 µg/mL, A + 300 µg/mL, A + 500 µg/mL	Song <i>et al.</i> [35]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	3T3-L1 cells	A + None, A + 25 µg/mL, A + 50 µg/mL, A + 100 µg/mL, A + 200 µg/mL, A + 400 µg/mL	Xie <i>et al.</i> [40]
Inhibited lipogenesis or promoted lipolysis	<i>Acer okamotoanum</i> Nakai	Leaf	Methanol extraction	-	3T3-L1 cells	P, A + None, A + 50 µg/mL, A + 100 µg/mL	Kim <i>et al.</i> [45]
	<i>Cirsium setidens</i> Naki	Leaf	Ethanol extraction	Pectolinarin	3T3-L1 cells	C, A + PC (<i>Garcinia cambogia</i> extract) 100 µg/mL, A + 100 µg/mL, A + 200 µg/mL	Cho <i>et al.</i> [36]
	<i>Cornus kousa</i>	Leaf	Ethanol extraction	Anthocyanins	3T3-L1 cells	A + None, A + 5 µg/mL, A + 30 µg/mL, A + 60 µg/mL, A + 100 µg/mL	Khan <i>et al.</i> [41]
	<i>Dendropanax morbifera</i>	Leaf	Water extraction	Vitamin C Tannic acid	3T3-L1 cells	P, A + None, A + 50 µg/mL, A + 100 µg/mL, A + 300 µg/mL, A + 500 µg/mL	Song <i>et al.</i> [35]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	3T3-L1 cells	A + None, A + 25 µg/mL, A + 50 µg/mL, A + 100 µg/mL, A + 200 µg/mL, A + 400 µg/mL	Xie <i>et al.</i> [40]

P, preadipocyte; A, adipocyte (differentiated cell); PC, positive control.

^{a,b,c} The ethanol extract mixture ratios of *Nelumbo Nucifera*, *L. Morus Alba* L., *Raphanus Sativus* — EM11 (100:0:0), EM12 (0:100:0), EM01 (80:20:0), respectively. ^d quercetin-3-O-glucuronide.

Table 3. TAnti-obesity mechanisms and biomarkers of Asian medicinal plants as demonstrated using *in vitro* models.

Mechanisms	Plants	Related biomarkers	References
Adipogenesis, lipogenesis, and lipolysis	<i>Acer okamotoanum</i> Nakai	PPAR γ ↓, C/EBP α ↓, SREBP1 ↓, FAS ↓	Kim <i>et al.</i> [45]
	<i>Astilbe dinensis</i> Franch. et Savat.	PPAR γ ↓, C/EBP α ↓, SREBP1 ↓, FAS ↓, SCD-1 ↓	Zhang <i>et al.</i> [44]
	<i>Cirsium setidens</i> Naki	PPAR γ ↓, C/EBP α ↓, C/EBP β ↓, C/EBP δ ↓ phospho-HSL ↑	Cho <i>et al.</i> [36]
	<i>Cornus kousa</i>	PPAR γ ↓, C/EBP α ↓, SREBP1 ↓, FAS ↓, aP2 ↓, LPL ↓	Khan <i>et al.</i> [41]
	<i>Dendropanax morbifera</i>	PPAR γ ↓, C/EBP α ↓, C/EBP β ↓, SREBP1 ↓	Song <i>et al.</i> [35]
	<i>Moringa oleifera</i>	PPAR γ ↓, C/EBP α ↓, C/EBP β ↓, FAS ↓ HSL ↑	Xie <i>et al.</i> [40]
Activation of the AMPK pathway	<i>Astilbe dinensis</i> Franch. et Savat.	Phospho-AMPK α ↑, phospho-ACC ↑, PGC-1 α ↑, PPAR α ↑, ATGL ↑, HSL ↑	Zhang <i>et al.</i> [44]
	<i>Cirsium setidens</i> Naki	Phospho-AMPK ↑, phospho-ACC ↑, CPT-1 ↑	Cho <i>et al.</i> [36]
	<i>Cornus kousa</i>	Phospho-AMPK ↑	Khan <i>et al.</i> [41]
	<i>Moringa oleifera</i>	Phospho-AMPK α (Thr172) ↑, phospho-ACC (Ser79) ↑	Xie <i>et al.</i> [40]
Inactivation of PI3K/AKT signaling	<i>Acer okamotoanum</i> Nakai	PI3K 110 α ↓, PI3K 110 β ↓, PI3K 110 δ ↓ phospho-AKT (Ser 473) ↓ phospho-mTOR (Ser 2481) ↓ phospho-p70S6K (Ser371) ↓	Kim <i>et al.</i> [45]
		β -Catenin ↑ phospho- β -catenin (Ser 552) ↑ phospho- β -catenin (Ser 33, 37/Thr 41) ↓ phospho-GSK3 β ↑	

plants. In addition, extracts of *Astilbe chinensis* Franch. et Savat. reduce the expression of stearoyl-CoA desaturase (SCD)-1, and extracts of *Cornus kousa* reduce the expression of aP2 and lipoprotein lipase (LPL) in 3T3-L1 differentiated adipocytes. Adipocyte-specific gene promoters, such as SCD-1, aP2, and LPL, are also well-known transcription factors that regulate adipogenesis and lipogenesis, as has been confirmed in several studies [54–56].

By contrast, promotion of lipolysis is also related to inhibition of lipid accumulation, and lipolysis-related biomarkers have been evaluated in adipocyte cell model studies. In this review, we found that treatment with *Moringa oleifera* and *Cirsium setidens* Naki upregulated hormone-sensitive lipase (HSL) protein levels and phosphorylation, respectively. HSL is a key regulator of TAG lipolysis [57].

The effects of *Astilbe chinensis* Franch. et Savat. and *Cornus kousa* on adipogenesis inhibition or lipolysis stimulation are mediated by activation of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway. Extracts of *Astilbe chinensis* Franch. et Savat. upregulate phospho-AMPK α and phospho-ACC as well as the mRNA levels of PPAR γ coactivator (PGC-1 α), PPAR α , adipose TG lipase (ATGL), and HSL in 3T3-L1 cells. This indicated that the extract of *Astilbe chinensis* Franch. et Savat. attenuates adipogenesis and promotes lipolysis via the AMPK pathway. Extracts of *Cornus kousa* also activate the phosphorylation of AMPK, whereas extracts of *Moringa oleifera* activate the phosphorylation of both AMPK α and ACC. Treatment with *Cirsium setidens* Naki extract promotes the metabolism of lipid synthesis to fatty acid oxidation through activation of the AMPK pathway, enhancing the phosphorylation of AMPK and ACC, the expression of CPT I, and the production of ATP.

Leaf extracts of *Acer okamotoanum* Nakai show anti-adipogenic activity by regulating phosphatidylinositol-3 kinase (PI3K)/AKT and β -catenin signaling. Treatment with *Acer okamotoanum* Nakai decreases the protein levels of PI3K 110 α , PI3K 110 β , PI3K 110 δ , and phospho-AKT (Ser 473). The PI3K/AKT signaling pathway is involved in stimulation of glucose uptake and adipocyte differentiation, and activation of PI3K and phosphorylation of AKT facilitates PPAR γ expression at the beginning of adipocyte differentiation. Thus, decreased levels of PI3K and phospho-Akt by *Acer okamotoanum* Nakai are linked to the suppression of insulin metabolism and lipid synthesis. Moreover, activation of the PI3K/AKT signaling pathway is associated with glucose uptake and 3T3-L1 adipogenesis in a chlorophyll pigment-derived branched-chain fatty alcohol, phytol [58]. In addition, in a study of *Acer okamotoanum* Nakai, mammalian target of rapamycin (mTOR) was found to be related to AKT downstream metabolism, whereas phosphorylation of ribosomal protein S6 kinase (p70S6K) was found to be related to the downstream metabolism of mTOR. Both factors, i.e., mTOR and p70S6K, are also involved in adipogenesis, and inhibition of mTOR and p70S6K phosphorylation resulting from attenuation of the PI3K/AKT signaling pathway decreases

adipocyte differentiation after treatment with *Acer okamotoanum* Nakai. Furthermore, inhibition of AKT and mTOR signaling pathways induces adipogenesis and lipogenesis, as demonstrated in a previous study of oligonol, an oligomerized polyphenol [59].

Treatment with *Acer okamotoanum* Nakai extract stimulates β -catenin signaling by inhibiting PPAR γ expression and preventing adipogenesis. The increased phosphorylation of glycogen synthase kinase 3 β , a key factor of β -catenin signaling, induces cytoplasmic β -catenin levels, and β -catenin is associated with inhibition of adipogenesis through down-regulation of PPAR γ activity.

5. Anti-obesity effects of Asian medicinal plants and their underlying mechanisms *in vivo*

As described in Table 4 (Ref. [36–40, 42–44, 46]), major anti-obesity activities *in vivo*, such as reduced body weight, adipose tissue weight (e.g., epididymal or retroperitoneal fat), and adipocyte size, have been demonstrated by all Asian medicinal plants discussed in this review. A high-fat diet (HFD) supplemented with extracts of *Astilbe chinensis* Franch. et Savat., *Cirsium setidens* Naki, *Cosmos caudatus* Kunth, *Melastoma malabathricum* var. *Alba* Linn, *Moringa oleifera*, a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, *Solidago virgaurea* var. *gigantea*, *Valeriana dageletiana* Nakai ex F. Maek., and *Viola mandshurica* W. Becker was provided to C57BL/6 or Sprague-Dawley rats for 7 to 14 weeks. The findings showed that supplementation with the extracts of most plants resulted in a decrease in serum lipid levels. Extracts of *Astilbe chinensis* Franch. et Savat., *Cosmos caudatus* Kunth, *Melastoma malabathricum* var. *Alba* Linn, and *Viola mandshurica* W. Becker reduce serum TG, total cholesterol (TC), and LDL-C levels. *Moringa oleifera* extracts decrease TC and LDL-C levels, and a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus* extracts decreases TC levels. Extracts of *Solidago virgaurea* var. *gigantea* and *Valeriana dageletiana* Nakai ex F. Maek. decrease TG and TC levels, whereas extracts of *Astilbe chinensis* Franch. et Savat., *Cosmos caudatus* Kunth, and *Viola mandshurica* W. Becker also show potential for controlling diabetes-related parameters by regulating glucose or insulin plasma levels. Additionally, extracts of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus* improve glucose levels in HFD-fed mice, as demonstrated in a glucose tolerance test. The effects of extracts of *Cirsium setidens* Naki, *Moringa oleifera*, a mixture of *Nelumbo Nucifera* L., *Morus Alba* L., and *Raphanus Sativus*, *Solidago virgaurea* var. *gigantea*, *Valeriana dageletiana* Nakai ex F. Maek, and *Viola mandshurica* W. Becker were also similar when compared to positive controls, *Garcinia cambogia*, Lovastatin, or Orlistat.

Anti-adipogenic effects on the liver have also been observed in medicinal plants. For example, extracts of *Cosmos caudatus* Kunth, *Melastoma malabathricum* var. *Alba* Linn, *Moringa oleifera*, and a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, *Solidago virgaurea* var. *gigantea*,

Table 4. Anti-obesity activities of Asian medicinal plants as demonstrated using *in vivo* models.

Activities	Plants	Plant part	Extraction	Major components	Animal model	Administration/Dose	Period	References
Reduced body weight, adipose tissue weight, and adipocyte size	<i>Astilbe chinensis</i> Franch. et Savat.	Whole plant	Ethanol extraction	Astilbic acid (Triterpenoids)	C57BL/6N	Supplementation with HFD ND, HFD, HFD + 100 mg/kg, HFD + 200 mg/kg	8 weeks	Zhang <i>et al.</i> [44]
	<i>Cirsium setidens</i> Naki	Leaf	Ethanol extraction	Pectolarin	C57BL/6J	Oral administration with HFD ND, HFD, HFD + 25 mg/kg/day, HFD + 50 mg/kg/day, HFD + 100 mg/kg/day, HFD + 200 mg/kg/day, HFD + PC (<i>Garcinia cambogia</i> extract) 100 mg/kg/day	14 weeks	Cho <i>et al.</i> [36]
	<i>Cosmos caudatus</i> Kunth	Leaf	Ethanol extraction	Quercetin, Catechin, Rutin, Chlorogenic acid	C57BL/6N	Supplementation with HFD ND, ND + 175 mg/kgBW, ND + 350 mg/kgBW, HFD, HFD + 175 mg/kgBW, HFD + 350 mg/kgBW	10 weeks	Rahman <i>et al.</i> [37]
	<i>Melastoma malabathricum</i> var. Alba Linn	Whole plant	Methanol extraction	Epicatechin, Flavonoids	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 5%	8 weeks	Karupiah <i>et al.</i> [43]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	C57BL/6N	Supplementation with HFD ND, HFD + PC (Lovastatin) 10 mg/kg, HFD + 0.125 g/kg, HFD + 0.25 g/kg, HFD + 0.5 g/kg	10 weeks	Xie <i>et al.</i> [40]
	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Leaf, leaf, root	Ethanol extraction	Quercetin-3-O-glucuronide	C57BL/6J	Oral administration with HFD ND, HFD, HFD + PC (<i>Garcinia cambogia</i>) 245 mg/kg, HFD + EM11 ^a 100 mg/kg, HFD + EM12 ^b 100 mg/kg, HFD + EM01 ^c 50 mg/kg, HFD + EM01 ^c 100 mg/kg, HFD + Q3OG ^d 10 mg/kg	8 weeks	Sim <i>et al.</i> [39]
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Whole plant	Ethanol extraction	Protocatechuic acid, Chlorogenic acid, Rutin	C57BL/6J	Oral administration with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 0.5% of 10% ethanol extract, HFD + 2% of 10% ethanol extract	7 weeks	Wang <i>et al.</i> [38]
	<i>Valeriana dageletiana</i> Nakai ex F. Maek	Stem and leaf	Ethanol extraction	Camphene, α -therpineol, Azulene, Geraniol	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 1%	8 weeks	Wang <i>et al.</i> [42]
	<i>Viola mandshurica</i> W. Becker	Whole plant	Ethanol and water extraction	Esculetin, Schaftoside	Sprague-Dawley rats	Oral administration with HFD ND, HFD, HFD + 200 mg/kg of ethanol extract, HFD + 100 mg/kg of ethanol extract, HFD + 50 mg/kg of ethanol extract, HFD + 200 mg/kg of water extract, HFD + 100 mg/kg of water extract, HFD + 50 mg/kg of water extract, HFD + PC1 (Orlistat) 50 mg/kg, HFD + PC2 (<i>Garcinia cambogia</i> extract) 100 mg/kg	11 weeks	Sung <i>et al.</i> [46]

Table 4. Continued.

Activities	Plants	Plant part	Extraction	Major Components	Animal model	Administration/Dose	Period	References
Decreased lipid levels of serum	<i>Astilbe diinensis</i> Franch. et Savat.	Whole plant	Ethanol extraction	Astilbic acid (Triterpenoids)	C57BL/6N	Supplementation with HFD ND, HFD, HFD+100 mg/kg, HFD+200 mg/kg	8 weeks	Zhang <i>et al.</i> [44]
	<i>Cosmos caudatus</i> Kunth	Leaf	Ethanol extraction	Quercetin, Catechin, Rutin, Chlorogenic acid	C57BL/6N	Supplementation with HFD ND, ND + 175 mg/kgBW, ND + 350 mg/kgBW, HFD, HFD + 175 mg/kgBW, HFD + 350 mg/kgBW	10 weeks	Rahman <i>et al.</i> [37]
	<i>Melastoma malabathricum</i> var <i>Alba</i> Linn	Whole plant	Methanol extraction	Epicatechin, Flavonoids	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 5%	8 weeks	Karupiah <i>et al.</i> [43]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	C57BL/6N	Supplementation with HFD ND, HFD + PC (Lovastatin) 10 mg/kg, HFD + 0.125 g/kg, HFD + 0.25 g/kg, HFD + 0.5 g/kg	10 weeks	Xie <i>et al.</i> [40]
	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Leaf, Leaf, Root	Ethanol extraction	Quercetin-3-O-glucuronide	C57BL/6J	Oral administration with HFD ND, HFD, HFD + PC (<i>Garcinia cambogia</i>) 245 mg/kg, HFD + EM11 100 mg/kg, HFD + EM12 100 mg/kg, HFD + EM01 50 mg/kg, HFD + EM01 100 mg/kg, HFD + Q3OG 10 mg/kg	8 weeks	Sim <i>et al.</i> [39]
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Whole plant	Ethanol extraction	Protocatechuic acid, Chlorogenic acid, Rutin	C57BL/6J	Oral administration with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 0.5% of 10% ethanol extract, HFD + 2% of 10% ethanol extract	7 weeks	Wang <i>et al.</i> [38]
	<i>Valeriana dageletiana</i> Nakai ex F. Maek.	Stem and leaf	Ethanol extraction	Camphene, α -therpineol, Azulene, Geraniol	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 1%	8 weeks	Wang <i>et al.</i> [42]
	<i>Viola mandshurica</i> W. Becker	Whole plant	Ethanol and water extraction	Esculetin, Schaftoside	Sprague-Dawley rats	Oral administration with HFD ND, HFD, HFD + 200 mg/kg of ethanol extract, HFD + 100 mg/kg of ethanol extract, HFD + 50 mg/kg of ethanol extract, HFD + 200 mg/kg of water extract, HFD + 100 mg/kg of water extract, HFD + 50 mg/kg of water extract, HFD + PC1 (Orlistat) 50 mg/kg, HFD + PC2 (<i>Garcinia cambogia</i> extract) 100 mg/kg	11 weeks	Sung <i>et al.</i> [46]

Table 4. Continued.

Activities	Plants	Plant part	Extraction	Major Components	Animal model	Administration/Dose	Period	References
Regulated plasma glucose and insulin levels	<i>Astilbe chinensis</i> Franch. et Savat.	Whole plant	Ethanol extraction	Astilbic acid (Triterpenoids)	C57BL/6N	Supplementation with HFD ND, HFD, HFD + 100 mg/kg, HFD + 200 mg/kg	8 weeks	Zhang <i>et al.</i> [44]
	<i>Cosmos caudatus</i> Kunth	Leaf	Ethanol extraction	Quercetin, Catechin, Rutin, Chlorogenic acid	C57BL/6N	Supplementation with HFD ND, ND + 175 mg/kgBW, ND + 350 mg/kgBW, HFD, HFD + 175 mg/kgBW, HFD + 350 mg/kgBW	10 weeks	Rahman <i>et al.</i> [37]
	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Leaf, Leaf, Root	Ethanol extraction	Quercetin-3-O-glucuronide	C57BL/6J	Oral administration with HFD ND, HFD, HFD + PC (<i>Garcinia cambogia</i>) 245 mg/kg, HFD + EM11 100 mg/kg, HFD + EM12 100 mg/kg, HFD + EM01 50 mg/kg, HFD + EM01 100 mg/kg, HFD + Q3OG 10 mg/kg	8 weeks	Sim <i>et al.</i> [39]
	<i>Viola mandshurica</i> W. Becker	Whole plant	Ethanol and water extraction	Esculetin, Schaftoside	Sprague-Dawley rats	Oral administration with HFD ND, HFD, HFD + 200 mg/kg of ethanol extract, HFD + 100 mg/kg of ethanol extract, HFD + 50 mg/kg of ethanol extract, HFD + 200 mg/kg of water extract, HFD + 100 mg/kg of water extract, HFD + 50 mg/kg of water extract, HFD + PC1 (Orlistat) 50 mg/kg, HFD + PC2 (<i>Garcinia combogia</i> extract) 100 mg/kg	11 weeks	Sung <i>et al.</i> [46]
Decreased liver weight and lipid accumulation in the liver	<i>Cosmos caudatus</i> Kunth	Leaf	Ethanol extraction	Quercetin, Catechin, Rutin, Chlorogenic acid	C57BL/6N	Supplementation with HFD ND, ND + 175 mg/kgBW, ND + 350 mg/kgBW, HFD, HFD + 175 mg/kgBW, HFD + 350 mg/kgBW	10 weeks	Rahman <i>et al.</i> [37]
	<i>Melastoma malabathricum</i> var Alba Linn	Whole plant	Methanol extraction	Epicatechin, Flavonoids	Sprague-Dawley rat	Supplementation with HFD ND, HFD, HFD + 5%	8 weeks	Karupiah <i>et al.</i> [43]
	<i>Moringa oleifera</i>	Leaf	Petroleum ether extract	Isoquercitrin, Chrysin-7-glucoside, Quercitrin	C57BL/6N	Supplementation with HFD ND, HFD + PC (Lovastatin) 10 mg/kg, HFD + 0.125 g/kg, HFD + 0.25 g/kg, HFD + 0.5 g/kg	10 weeks	Xie <i>et al.</i> [40]

Table 4. Continued.

Activities	Plants	Plant part	Extraction	Major Components	Animal model	Administration/Dose	Period	References
Reduced hepatic lipid metabolites	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Leaf, leaf, root	Ethanol extraction	Quercetin-3-O-glucuronide	C57BL/6J	Oral administration with HFD ND, HFD, HFD + PC (<i>Garcinia cambogia</i>) 245 mg/kg, HFD + EM11 100 mg/kg, HFD + EM12 100 mg/kg, HFD + EM01 50 mg/kg, HFD + EM01 100 mg/kg, HFD + Q3OG 10 mg/kg	8 weeks	Sim <i>et al.</i> [39]
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Whole plant	Ethanol extraction	Protocatechuic acid, Chlorogenic acid, Rutin	C57BL/6J	Oral administration with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 0.5% of 10% ethanol extract, HFD + 2% of 10% ethanol extract	7 weeks	Wang <i>et al.</i> [38]
	<i>Valeriana dageletiana</i> Nakai ex F. Maek	Stem and leaf	Ethanol extraction	Camphene, α -therpin-eol, Azulene, Geraniol	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 1%	8 weeks	Wang <i>et al.</i> [42]
	<i>Viola mandshurica</i> W. Becker	Whole plant	Ethanol and water extraction	Esculetin, Schaftoside	Sprague-Dawley rats	Oral administration with HFD ND, HFD, HFD + 200 mg/kg of ethanol extract, HFD + 100 mg/kg of ethanol extract, HFD + 50 mg/kg of ethanol extract, HFD + 200 mg/kg of water extract, HFD + 100 mg/kg of water extract, HFD + 50 mg/kg of water extract, HFD + PC1 (Orlistat) 50 mg/kg, HFD + PC2 (<i>Garcinia cambogia</i> extract) 100 mg/kg	11 weeks	Sung <i>et al.</i> [46]
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Whole plant	Ethanol extraction	Protocatechuic acid, Chlorogenic acid, Rutin	C57BL/6J	Oral administration with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 0.5% of 10% ethanol extract, HFD + 2% of 10% ethanol extract	7 weeks	Wang <i>et al.</i> [38]
	<i>Valeriana dageletiana</i> Nakai ex F. Maek.	Stem and leaf	Ethanol extraction	Camphene, α -therpin-eol, Azulene, Geraniol	Sprague-Dawley rats	Supplementation with HFD ND, HFD, HFD + 1% PC (<i>Garcinia cambogia</i> extract), HFD + 1%	8 weeks	Wang <i>et al.</i> [42]

ND, normal diet; HFD, high-fat diet; PC, positive control.

^{a,b,c} The ethanol extract mixture ratios of *Nelumbo Nucifera* L., *Morus Alba* L., *Raphanus Sativus* — EM11 (100:0:0), EM12 (0:100:0), EM01 (80:20:0), respectively.

^d quercetin-3-O-glucuronide.

Valeriana dageletiana Nakai ex F. Maek., and *Viola mandshurica* W. Becker decrease liver weight and lipid accumulation in the liver. In particular, *Moringa oleifera* reduces hepatic TG levels. Furthermore, several medicinal plants, including *Solidago virgaurea* var. *gigantea* and *Valeriana dageletiana* Nakai ex F. Maek, lower hepatic lipid metabolite levels, as measured using nuclear magnetic resonance. Both plants reduce the levels of fatty acids, cholesterol, phospholipids, and lipid moieties, which are induced by consumption of an HFD. Extracts of *Cosmos caudatus* Kunth or a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, *Solidago virgaurea* var. *gigantea*, *Viola mandshurica* W. Becker, and *Valeriana dageletiana* Nakai ex F. Maek. were also used for evaluation of liver function and toxicity by analyzing aspartate transaminase, alanine transferase, and gamma-glutamyl transferase levels.

Similar to the results of *in vitro* studies, obesity-related mechanisms and biomarkers have also been identified from *in vivo* studies (Table 5, Ref. [38–40, 42, 44, 46]). Supplementation with extracts of *Astilbe chinensis* Franch. et Savat. downregulates PPAR γ , C/EBP α , SERBP1, FAS, and SCD-1, and extracts of *Viola mandshurica* W. Becker downregulates C/EBP α , C/EBP β , and SREBP1c in epididymal adipose tissue, whereas extracts of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus* decrease the expression of PPAR γ , SERBP1c, FAS, SCD-1, and DGAT1 in liver and epididymal adipose tissues. Specifically, extracts of a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, and *Viola mandshurica* W. Becker increase the gene expression of PPAR α , uncoupling protein (UCP)-1, and UCP-2 in adipose tissue and abdominal subcutaneous fat. Moreover, extracts of *Moringa oleifera* decreases the expression of PPAR γ and FAS and increase the expression of ATGL by controlling lipolysis in epididymal adipose tissue and the liver. Furthermore, extracts of *Solidago virgaurea* var. *gigantea* reduce the expression of PPAR γ , C/EBP α , aP2, FAS, and SCD-1 by inhibiting adipogenesis in epididymal tissue and suppress the expression SREBP1c, FAS, SCD-1, and CD36 by inhibiting lipogenesis in the liver. Hence, the expression of adipogenesis- and lipogenesis-related genes, including PPAR γ , C/EBP α , aP2, FAS, and SCD-1, is downregulated in epididymal white adipose tissue, whereas the expression of lipogenesis-related genes, including SERBP1c, FAS, SCD-1, and CD36, is downregulated in liver by treatment with extracts of *Valeriana dageletiana* Nakai ex F. Maek.

The AMPK pathway is a well-known mechanism that regulates lipid metabolism. Several medicinal plants have been evaluated to determine their ability to regulate lipolysis through the activation of AMPK signaling in the adipose tissue and liver of HFD-induced obese mice. Extracts of *Astilbe chinensis* Franch. et Savat. promote AMPK pathways by increasing the protein levels of phospho-AMPK, phospho-ACC, and PGC-1 α and the levels of lipolysis-related targets, such as ATGL and phospho-HSL, in epididymal adipose tissue. In addition, extracts of *Moringa oleifera* stimulate the

phosphorylation of AMPK α (Thr172) and ACC (Ser79) in epididymal adipose tissue and the liver by inhibiting adipogenesis. Moreover, the mRNA expression of AMPK α 1 and AMPK α 2 is upregulated in both epididymal adipose tissue and the liver, and the levels of phospho-AMPK and ACC are upregulated in the liver after supplementation with *Viola mandshurica* W. Becker extract.

6. Conclusions

Various species of medicinal plants originate from Asian countries, including Korea, China, Japan, India, and Malaysia. Plants are generally extracted with ethanol, and flavonoids, such as quercetin, as well as catechin, anthocyanins, and other phenolic acids are the major components of these plants. The effects of Asian medicinal plants on obesity have been examined through many *in vitro* and *in vivo* studies. In this study, we found that eight types of Asian medicinal plants, including *Acer okamotoanum* Nakai, *Astilbe chinensis* Franch. et Savat., *Cirsium setidens* Naki, *Cornus kousa*, *Dendropanax morbifera*, *Moringa oleifera*, a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus*, and *Solidago virgaurea* var. *gigantea*, reduce intercellular lipid accumulation and decrease the sizes and numbers of lipid droplets during adipogenesis. These plants also inhibit lipogenesis or promote lipolysis in 3T3-L1 cells. The major transcription factors related to adipogenesis and lipogenesis are PPAR γ , C/EBP α , C/EBP β , SREBP1, and FAS. In particular, upregulation of lipolysis via the AMPK pathway has been observed in several medicinal plants. Additionally, we evaluated the effects of nine types of Asian medicinal plants, including *Astilbe chinensis* Franch. et Savat., *Cirsium setidens* Naki, *Cosmos caudatus* Kunth, *Melastoma malabathricum* var. *Alba* Linn, *Moringa oleifera*, *Solidago virgaurea* var. *gigantea*, *Valeriana dageletiana* Nakai ex F. Maek, *Viola mandshurica* W. Becker, and a mixture of *Nelumbo nucifera* L., *Morus alba* L., and *Raphanus sativus* on obesity in HFD-induced obesity mouse models. The results showed that supplementation with these medicinal plants reduces body weight, adipose tissue weight, and adipocyte size; decreases serum lipid levels; regulates glucose and insulin levels; and improves lipid accumulation in the liver. Similar to *in vitro* studies, these *in vivo* reports showed that the expression levels of PPAR γ , C/EBP α , C/EBP β , SREBP1, FAS, SCD-1, CD36, UCP-1, UCP-2, and ATGL are related to adipogenesis, lipogenesis, and lipolysis in the adipose tissue and liver. The possible anti-obesity mechanisms and related biomarkers of Asian medicinal plants from this study is illustrated in Fig. 1. Although many studies have reported the anti-obesity effects of Asian plants, most results have been reported from *in vitro* or *in vivo* studies, and there is a lack of clear evidence demonstrating these effects, as well as the safety of the medicines, in the human body. Furthermore, the mechanisms of absorption and metabolism, as well as the effects of the medicinal plants on various tissues and organs, as related to their anti-obesity effects, have still not been elucidated. Studies on the signaling

Table 5. Anti-obesity mechanisms and biomarkers of Asian medicinal plants as demonstrated using *in vivo* models.

Mechanisms	Plants	Related organs	Related biomarkers	References
Adipogenesis and lipogenesis in adipose tissue and the liver	<i>Astilbe chinensis</i> Franch. et Savat.	Epididymal adipose tissue	PPAR γ \downarrow , C/EBP α \downarrow , SERBP1 \downarrow , FAS \downarrow , SCD-1 \downarrow	Zhang <i>et al.</i> [44]
	<i>Moringa oleifera</i>	Epididymal adipose tissue, liver	PPAR γ \downarrow , FAS \downarrow	Xie <i>et al.</i> [40]
	<i>Nelumbo Nucifera</i> L., <i>Morus Alba</i> L., <i>Raphanus Sativus</i>	Liver, epididymal adipose tissue	PPAR γ \downarrow , SREBP1c \downarrow , FAS \downarrow , SCD-1 \downarrow , DGAT1 \downarrow	Sim <i>et al.</i> [39]
		Adipose tissue, abdominal subcutaneous fat tissue	PPAR α \uparrow , UCP-1 \uparrow , UCP-2 \uparrow	
	<i>Solidago virgaurea</i> var. <i>gigantea</i>	Epididymal adipose tissue	PPAR γ \downarrow , C/EBP α \downarrow , aP2 \downarrow , FAS \downarrow , SCD-1 \downarrow	Wang <i>et al.</i> [38]
	<i>Valeriana dageletiana</i> Nakai ex F. Maek.	Liver	SREBP1c \downarrow , FAS \downarrow , SCD-1 \downarrow , CD36 \downarrow	
		Epididymal white adipose tissue	PPAR γ \downarrow , C/EBP α \downarrow , aP2 \downarrow , FAS \downarrow , SCD-1 \downarrow	Wang <i>et al.</i> [42]
		Liver	SREBP1c \downarrow , FAS \downarrow , SCD-1 \downarrow , CD36 \downarrow	
Lipolysis in adipose tissue and the liver	<i>Viola mandshurica</i> W. Becker	Epididymal adipose tissue	C/EBP α \downarrow , C/EBP β \downarrow , SREBP1c \downarrow	Sung <i>et al.</i> [46]
	<i>Astilbe chinensis</i> Franch. et Savat.	Adipose tissue, abdominal subcutaneous fat tissue	UCP-2 \uparrow	
Inhibitory effects of lipid accumulation by AMPK activation in adipose tissue and the liver	<i>Moringa oleifera</i>	Epididymal adipose tissue	ATGL \uparrow , phospho-HSL \uparrow	Zhang <i>et al.</i> [44]
		Epididymal adipose tissue, liver	ATGL \uparrow	Xie <i>et al.</i> [40]
	<i>Astilbe chinensis</i> Franch. et Savat.	Epididymal adipose tissue	Phospho-AMPK \uparrow , phospho-ACC \uparrow , PGC-1 α \uparrow	Zhang <i>et al.</i> [44]
	<i>Moringa oleifera</i>	Epididymal adipose tissue, liver	Phospho-AMPK α (Thr172) \uparrow , Phospho-ACC (Ser79) \uparrow	Xie <i>et al.</i> [40]
	<i>Viola mandshurica</i> W. Becker	Epididymal adipose tissue	AMPK α 1 \uparrow , AMPK α 2 \uparrow	Sung <i>et al.</i> [46]
		Liver	Phospho-AMPK \uparrow , ACC \uparrow	




Fig. 1. Anti-obesity effects of Asian medicinal plants and their underlying mechanisms *in vitro* and *in vivo* models. Asian medicinal plants inhibit fat accumulation and promote lipolysis by AMPK activation, PI3K/AKT signaling inactivation, and activation of β -catenin signaling pathway.

pathways and biomarkers of anti-obesity have also been insufficient. Therefore, further studies are needed to improve our knowledge of these aspects in the future. Nevertheless, the findings from this review highlight the anti-obesity effects of Asian medicinal plants and support the use of these plants as alternative medicines for obesity prevention.

Abbreviations

UCP1, uncoupling protein 1; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; C/EBP, CCAAT/enhancer binding protein; PPAR, peroxisome proliferator-activated receptor; FAS, fatty acid synthase; FABP4, fatty acid binding protein 4; aP2, adipocyte protein 2; SREBP, sterol regulatory element binding protein; ACC, acetyl-CoA carboxylase; CPT-1, carnitine palmitoyl transferase-1; LPL, lipoprotein lipase; SCD, stearoyl-CoA desaturase; HSL, hormone-sensitive lipase; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; PGC, peroxisome proliferator-activated receptor gamma coactivator; ATGL, adipose triglyceride lipase; PI3K, phosphatidylinositol-3 kinase; mTOR, mammalian target of rapamycin; p70S6K, phosphorylation of ribosomal protein S6 kinase; HFD, high-fat diet; TC, total cholesterol; UPC, uncoupling protein.

Author contributions

JTH received a review invitation; SC and JTH developed the research question, and SC and SHP collected and screened the relevant articles; JHP and JTH selected the final articles and extracted the data from the articles; SC wrote the

manuscript; All authors critically reviewed the manuscript and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

Funding

This study was funded by a research grant from the Korea Food Research Institute (Project Number: E0210601), Republic of Korea.

Conflict of interest

The authors declare no conflict of interest.

References

- [1] NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet*. 2016; 387: 1377–1396.
- [2] World Health Organization. Obesity and overweight. 2021. Available at: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (Accessed: 17 August 2021).
- [3] Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. *Journal of Clinical Endocrinology and Metabolism*. 2008; 93: S64–S73.
- [4] Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *Journal of the American Medical Association*. 1999; 282: 1523–1529.

- [5] Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. *Physiology Reviews*. 2015; 95: 727–748.
- [6] Haslam DW, James WPT. Obesity. *The Lancet*. 2005; 366: 1197–1209.
- [7] Nimptsch K, Pischon T. Body fatness, related biomarkers and cancer risk: an epidemiological perspective. *Hormone Molecular Biology and Clinical Investigation*. 2015; 22: 39–51.
- [8] Cheung BMY, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. *Therapeutic Advances in Drug Safety*. 2013; 4: 171–181.
- [9] Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH. Anti-Obesity Therapy: from Rainbow Pills to Polygonists. *Pharmacological Reviews*. 2018; 70: 712–746.
- [10] Salehi B, Ata A, V Anil Kumar N, Sharopov F, Ramirez-Alarcon K, Ruiz-Ortega A, *et al*. Antidiabetic potential of medicinal plants and their active components. *Biomolecules*. 2019; 9: 551.
- [11] Payab M, Hasani-Ranjbar S, Shahbal N, Qorbani M, Aletaha A, Haghi-Aminjan H, *et al*. Effect of the herbal medicines in obesity and metabolic syndrome: a systematic review and meta-analysis of clinical trials. *Phytotherapy Research*. 2020; 34: 526–545.
- [12] Jayawardena R, Sooriyaarachchi P, Ranasinghe P, Perera A, Hills AP. Availability and composition of weight-loss supplements in Sri Lanka. *Nutrition & Dietetics*. 2020; 77: 247–252.
- [13] Kim S, Oh M, Kim M, Chae H, Chae S. Anti-obesity effects of Yerba Mate (*Ilex Paraguariensis*): a randomized, double-blind, placebo-controlled clinical trial. *BMC Complementary and Alternative Medicine*. 2015; 15: 338.
- [14] Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (*Phaseolus vulgaris*): a review of clinical studies on weight loss and glycemic control. *Nutrition Journal*. 2011; 10: 24.
- [15] Blanck HM, Khan LK, Serdula MK. Use of Nonprescription Weight Loss Products. *Journal of the American Medical Association*. 2001; 286: 930.
- [16] Batis JA, Apolzan JW, Bagley PJ, Blunt HB, Divan V, Gill S, *et al*. A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss. *Obesity*. 2021; 29: 1102–1113.
- [17] Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, *et al*. Traditional Chinese medicine and Kampo: a review from the distant past for the future. *The Journal of International Medical Research*. 2006; 34: 231–239.
- [18] He K. Traditional Chinese and Thai medicine in a comparative perspective. *Complementary Therapies in Medicine*. 2015; 23: 821–826.
- [19] Riswan S, Roemantyo S. Jamu as traditional medicine in Java, Indonesia. *South Pacific Study*. 2002; 23.
- [20] Kunwar RM, Nepal BK, Kshhetri HB, Rai SK, Bussmann RW. Ethnomedicine in Himalaya: a case study from Dolpa, Humla, Jumla and Mustang districts of Nepal. *Journal of Ethnobiology and Ethnomedicine*. 2006; 2: 27.
- [21] Vasisht K, Sharma N, Karan M. Current Perspective in the International Trade of Medicinal Plants Material: an Update. *Current Pharmaceutical Design*. 2016; 22: 4288–4336.
- [22] Astutik S, Pretzsch J, Kimengsi JN. Asian medicinal plants' production and utilization potentials: a review. *Sustainability Basel*. 2019; 11: 5843.
- [23] World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization: Geneva, Switzerland. 2000.
- [24] Church C, Horowitz M, Rodeheffer M. WAT is a functional adipocyte? *Adipocyte*. 2012; 1: 38–45.
- [25] Cinti S, Frederich RC, Zingaretti MC, De Matteis R, Flier JS, Lowell BB. Immunohistochemical localization of leptin and uncoupling protein in white and brown adipose tissue. *Endocrinology*. 1997; 138: 797–804.
- [26] Mandrup S, Lane MD. Regulating adipogenesis. *The Journal of Biological Chemistry*. 1997; 272: 5367–5370.
- [27] Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. *Fitoterapia*. 2010; 81: 358–366.
- [28] Ducharme NA, Bickel PE. Lipid droplets in lipogenesis and lipolysis. *Endocrinology*. 2008; 149: 942–949.
- [29] Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. *Metabolism: Clinical and Experimental*. 2019; 92: 71–81.
- [30] Moseti D, Regassa A, Kim W. Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules. *International Journal of Molecular Sciences*. 2016; 17: 124.
- [31] Oh S, Park S, Kim J, Ahn Y, Park S, Kim K. Acetyl-CoA carboxylase beta gene is regulated by sterol regulatory element-binding protein-1 in liver. *The Journal of Biological Chemistry*. 2003; 278: 28410–28417.
- [32] Ruderman NB, Saha AK, Kraegen EW. Minireview: Malonyl CoA, AMP-Activated Protein Kinase, and Adiposity. *Endocrinology*. 2003; 144: 5166–5171.
- [33] Freytag SO, Utter MF. Regulation of the synthesis and degradation of pyruvate carboxylase in 3T3-L1 cells. *Journal of Biological Chemistry*. 1983; 258: 6307–6312.
- [34] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1999; 19: 972–978.
- [35] Song J, Kang H, Kim JH, Kwak S, Sung G, Park S, *et al*. Antiobesity and Cholesterol-Lowering Effects of *Dendropanax moribifera* Water Extracts in Mouse 3T3-L1 Cells. *Journal of Medicinal Food*. 2018; 21: 793–800.
- [36] Cho B, Park M, Lee J, Ra M, Han KC, Kang I, *et al*. Standardized *Cirsium setidens* Nakai Ethanolic Extract Suppresses Adipogenesis and Regulates Lipid Metabolisms in 3T3-L1 Adipocytes and C57BL/6J Mice Fed High-Fat Diets. *Journal of Medicinal Food*. 2017; 20: 763–776.
- [37] Rahman HA, Sahib NG, Saari N, Abas F, Ismail A, Mumtaz MW, *et al*. Anti-obesity effect of ethanolic extract from *Cosmos caudatus* Kunth leaf in lean rats fed a high fat diet. *BMC Complementary and Alternative Medicine*. 2017; 17: 122.
- [38] Wang Z, Kim JH, Jang YS, Kim CH, Lee J, Lim SS. Anti-obesity effect of *Solidago virgaurea* var. *gigantea* extract through regulation of adipogenesis and lipogenesis pathways in high-fat diet-induced obese mice (C57BL/6N). *Food & Nutrition Research*. 2017; 61: 1273479.
- [39] Sim W, Choi S, Cho B, Choi S, Han X, Cho H, *et al*. Anti-Obesity Effect of Extract from *Nelumbo Nucifera* L., *Morus Alba* L., and *Raphanus Sativus* Mixture in 3T3-L1 Adipocytes and C57BL/6J Obese Mice. *Foods*. 2019; 8: 170.
- [40] Xie J, Wang Y, Jiang WW, Luo XF, Dai TY, Peng L, *et al*. *Moringa oleifera* leaf petroleum ether extract inhibits lipogenesis by activating the AMPK signaling pathway. *Frontiers in Pharmacology*. 2018; 9: 1447.
- [41] Khan MI, Shin JH, Shin TS, Kim MY, Cho NJ, Kim JD. Anthocyanins from *Cornus kousa* ethanolic extract attenuate obesity in association with anti-angiogenic activities in 3T3-L1 cells by down-regulating adipogenesis and lipogenesis. *PLoS ONE*. 2018; 13: e0208556.
- [42] Wang Z, Hwang SH, Kim JH, Lim SS. Anti-obesity effect of the above-ground part of *Valeriana dageletiana* Nakai ex F. Maek extract in high-fat diet-induced obese C57BL/6N mice. *Nutrients*. 2017; 9: 689.
- [43] Karupiah S, Ismail Z. Anti-Obesity Effects of *Melastoma malabathricum* var *Alba* Linn in Rats Fed with a High-Fat Diet. *AAPS PharmSciTech*. 2015; 16: 548–553.
- [44] Zhang XH, Wang Z, Kang B, Hwang SH, Lee J, Lim SS, *et al*. Antiobesity Effect of *Astilbe chinensis* Franch. et Savet. Extract through Regulation of Adipogenesis and AMP-Activated Protein Kinase Pathways in 3T3-L1 Adipocyte and High-Fat Diet-Induced C57BL/6N Obese Mice. *Evidence-Based Complementary and Alternative Medicine*. 2018; 2018: 1347612.
- [45] Kim EJ, Kang MJ, Seo YB, Nam SW, Kim GD. *Acer okamotoanum* Nakai leaf extract inhibits adipogenesis via suppressing expression

- of PPAR gamma and C/EBP alpha in 3T3-L1 cells. *Journal of Microbiology and Biotechnology*. 2018; 28: 1645–1653.
- [46] Sung Y, Kim D, Kim S, Kim HK. Anti-obesity activity, acute toxicity, and chemical constituents of aqueous and ethanol *Viola mandshurica* extracts. *BMC Complementary and Alternative Medicine*. 2017; 17: 297.
- [47] Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis. *European Journal of Cell Biology*. 2013; 92: 229–236.
- [48] Lefterova MI, Lazar MA. New developments in adipogenesis. *Trends in Endocrinology and Metabolism*. 2009; 20: 107–114.
- [49] Kim YM, Kim IH, Choi JW, Lee MK, Nam TJ. The anti-obesity effects of a tuna peptide on 3T3-L1 adipocytes are mediated by the inhibition of the expression of lipogenic and adipogenic genes and by the activation of the Wnt/beta-catenin signaling pathway. *International Journal of Molecular Medicine*. 2015; 36: 327–334.
- [50] Lewis YS, Neelakantan S. (–)-Hydroxycitric acid—the principal acid in the fruits of *Garcinia cambogia* desr. *Phytochemistry*. 1965; 4: 619–625.
- [51] Kim K, Lee HN, Kim YJ, Park T. *Garcinia cambogia* extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. *Bioscience, Biotechnology, and Biochemistry*. 2008; 72: 1772–1780.
- [52] Cowherd RM, Lyle RE, McGehee RE. Molecular regulation of adipocyte differentiation. *Seminars in Cell & Developmental Biology*. 1999; 10: 3–10.
- [53] Paulauskis JD, Sul HS. Cloning and expression of mouse fatty acid synthase and other specific mRNAs. Developmental and hormonal regulation in 3T3-L1 cells. *The Journal of Biological Chemistry*. 1988; 263: 7049–7054.
- [54] Lee M, Sung SH. Platyphylloside isolated from *Betula platyphylla* inhibit adipocyte differentiation and induce lipolysis via regulating adipokines including PPARgamma in 3T3-L1 cells. *Pharmacognosy Magazine*. 2016; 12: 276–281.
- [55] Lee M, Sorn SR, Lee Y, Kang I. Salt Induces Adipogenesis/Lipogenesis and Inflammatory Adipocytokines Secretion in Adipocytes. *International Journal of Molecular Sciences*. 2019; 20: 160.
- [56] Ranganathan G, Unal R, Pokrovskaya I, Yao-Borengasser A, Phanavanh B, Lecka-Czernik B, *et al.* The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. *Journal of Lipid Research*. 2006; 47: 2444–2450.
- [57] Egan JJ, Greenberg AS, Chang MK, Wek SA, Moos MC, Londos C. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. *Proceedings of the National Academy of Sciences of the United States of America*. 1992; 89: 8537–8541.
- [58] Wang J, Hu X, Ai W, Zhang F, Yang K, Wang L, *et al.* Phytol increases adipocyte number and glucose tolerance through activation of PI3K/Akt signaling pathway in mice fed high-fat and high-fructose diet. *Biochemical and Biophysical Research Communications*. 2017; 489: 432–438.
- [59] Park JY, Kim Y, Im JA, You S, Lee H. Inhibition of adipogenesis by oligonol through Akt-mTOR inhibition in 3T3-L1 adipocytes. *Evidence Based Complementary and Alternative Medicine*. 2014; 2014: 895272.